Navigation Links
Dynatronics Will Request Hearing with Nasdaq Regarding Listing Status
Date:11/8/2012

SALT LAKE CITY, Nov. 8, 2012 /PRNewswire/ -- Dynatronics Corporation (Nasdaq: DYNT) today announced that on November 7, 2012, the Company received a Nasdaq Staff Determination Letter indicating that the Company has not complied with the $1.00 minimum bid rule for continued listing set forth in Listing Rule 5550(a)(2) and faces delisting from the Nasdaq Capital Market at the opening of business on November 16, 2012, unless the Company requests an appeal of the determination by the staff.

The Company will request an appeal of the delisting determination pursuant to procedures available under the Nasdaq Listing Rules.  The hearing panel is authorized to grant additional time to regain compliance, if the panel deems it appropriate. The Company's hearing request will stay the suspension of the Company's securities pending the hearing and a final determination by the panel. As part of its appeal, the Company will be required to provide the panel with a plan to regain compliance.  The Company's plan includes a commitment to effect a reverse stock split, if necessary.

"We have filed a definitive proxy statement requesting shareholder approval for a 1 for 5 reverse stock split to regain compliance," stated Kelvyn H. Cullimore, Jr., chairman and president of Dynatronics.  "With several positive developments taking place at the Company, including the recently announced introduction of our Dynatronics SolarisPlus product line and Quad7 products, we believe Dynatronics has a strong future and will be granted the time under our plan necessary to effect our reverse split in order to regain compliance with the rule."

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.


'/>"/>
SOURCE Dynatronics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dynatronics To Release Fiscal Third Quarter Results Tuesday, May 15, 2012; Conference Call set for 3:30 p.m. ET
2. Dynatronics Introduces New SolarisPlus Line of Therapy Products
3. Watson and Actavis Receive FTC Second Request
4. BHI Raises Awareness of Hearing Aids as Potential Therapy to Help Quiet "Ringing in the Ears" During National Tinnitus Awareness Week
5. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
6. Kill the Germs, Spare the Ears: Study Shows How to Create Effective Antibiotics That Dont Damage Hearing
7. United States ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
8. United Kingdom ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
9. China ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
10. India ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
11. Hearing Loss Could Lead to Multiple Chronic Diseases for Millions of Brits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)... -- Bayer announced today that the latest research from across ... 53 rd Annual Meeting of the American Society ... Chicago . The ... and thyroid cancers, as well as lymphomas, and includes ... of copanlisib in patients with relapsed or refractory follicular ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with ... every IT system, from the datacenter to the cloud to the edge. Through ...
(Date:5/24/2017)... ... 24, 2017 , ... The CFOs included on this list ... in the nation and help their organizations navigate the challenges in healthcare today. ... in developing successful hospital and health system strategy. , Becker's Hospital Review has ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a ... today that its iClinic V12.2 solution has achieved approval from National Center for ... PCMH 2017 standards which emphasize team-based care with a significant focus on the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May ... since 2009, according to a Workers Compensation Research Institute (WCRI) study, a contrast ... North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical ...
(Date:5/23/2017)... ... 2017 , ... London, May 23, 2017: Walter Schindler, the Founder and Managing ... Guest Speaker and Contributor to a weeklong series of classes, meetings, field trips and ... , Walter Schindler and SAIL Capital have received an increasing number ...
Breaking Medicine News(10 mins):